Latest / DoctorX.AI / 【EN】The Next Apple? Why 2026 Illumina is Mirroring 2012 AAPL
Transcript
- 0:00SPEAKER_01: Welcome back to the Deep Dive.
- 0:01SPEAKER_01: It is Saturday, January 17th, 2026.
- 0:04SPEAKER_01: The markets are closed.
- 0:05SPEAKER_01: The noise of the trading week has settled.
- 0:07SPEAKER_01: And today we're doing something a little different.
- 0:09SPEAKER_01: Usually we cast a pretty wide net.
- 0:11SPEAKER_01: But today, well,
- 0:14SPEAKER_01: Today we're putting on our forensic accounting hats.
- 0:16SPEAKER_01: We are treating you,
- 0:17SPEAKER_01: the listener,
- 0:18SPEAKER_01: not just as a casual observer,
- 0:19but as a professional capital allocator looking for that
- 0:23elusive margin of safety.
- 0:25SPEAKER_00: That's right.
- 0:26We're looking at a specific company that has been through the
- 0:28absolute ringer over
- 0:29SPEAKER_00: the last five years.
- 0:30SPEAKER_00: We're talking about a fallen angel,
- 0:32SPEAKER_00: a massive corporate governance disaster,
- 0:34SPEAKER_00: and if the data on the table is correct,
- 0:36SPEAKER_00: a textbook turnaround story.
- 0:38SPEAKER_00: We are looking at Illumia, ticker ILMN.
- 0:40SPEAKER_01: And just to set the expectations early,
- 0:42our mission today is to figure out how this company went from
- 0:44being the absolute
- 0:45SPEAKER_01: darling of the biotech world in,
- 0:47SPEAKER_01: say,
- 0:482018 to what many people called a broken growth stock in 2023
- 0:52and where it actually
- 0:53SPEAKER_01: stands right now in early 2026.
- 0:55SPEAKER_01: We're just reading headlines.
- 0:56SPEAKER_01: We have the 10Ks going back eight years.
- 0:58We have the quarterly reports from 2025 and that fresh
- 1:00presentation from the JPM
- 1:02SPEAKER_01: conference just a few days ago.
- 1:04SPEAKER_00: Precisely.
- 1:05SPEAKER_00: And the ground rules for this deep dive are simple.
- 1:08SPEAKER_00: No fluff.
- 1:09SPEAKER_00: We're looking at return on invested capital,
- 1:12SPEAKER_00: we're scrutinizing capital allocation,
- 1:14SPEAKER_00: and we're stress testing the business model.
- 1:16SPEAKER_00: Because the thesis we're exploring is, well, it's controversial.
- 1:20The numbers suggest that Illumina in 2026 looks a lot like
- 1:24Apple did in 2012.
- 1:25SPEAKER_01: OK, I want to put a pin in that immediately.
- 1:27SPEAKER_01: Illumina is the Apple of 2012.
- 1:29SPEAKER_01: That is a massive claim.
- 1:31You're comparing a biotech hardware company to the greatest
- 1:34consumer electronics
- 1:35SPEAKER_01: business in history.
- 1:37SPEAKER_01: Are you saying this is a mispriced monopoly hiding in plain sight?
- 1:40SPEAKER_00: I know it sounds hyperbolic,
- 1:41SPEAKER_00: but to understand why that comparison actually holds water,
- 1:44SPEAKER_00: you have to strip away all the stock price action of the last few years.
- 1:47SPEAKER_00: You have to look at the engine inside the machine.
- 1:50SPEAKER_00: You have to understand the fundamental shift in the business model.
- 1:53SPEAKER_01: Let's look under the hood then.
- 1:54If we rewind to the 2018 10K,
- 1:56Illumina was already the dominant player in genomic sequencing.
- 2:00SPEAKER_01: They make the machines that read DNA.
- 2:03SPEAKER_01: But the way they made money then was different from today, right?
- 2:06SPEAKER_00: It was significantly different.
- 2:07SPEAKER_00: In 2018, they were still very much in a hardware growth cycle.
- 2:10SPEAKER_00: But even then, even then they had this beautiful razor and blade model.
- 2:14SPEAKER_00: You sell the sequencer,
- 2:15SPEAKER_00: that's the razor,
- 2:16SPEAKER_00: and then you sell the consumables,
- 2:18SPEAKER_00: the blades,
- 2:18SPEAKER_00: to run it.
- 2:19SPEAKER_00: Back in 2018, consumables were about 65% of their revenue.
- 2:23SPEAKER_01: Which is already a great business.
- 2:25But fast forward to the data we have for 2024 and 2025,
- 2:28that mix has shifted aggressively.
- 2:31SPEAKER_00: It really has.
- 2:32In the reports for 2024 and 2025,
- 2:35consumables revenue climbed to over 72% of the total.
- 2:38And if you look at the JPM 2026 update we just got,
- 2:42they're now flagging recurring revenue.
- 2:44which they define as consumables plus service contracts,
- 2:47at approximately 90 percent.
- 2:48SPEAKER_01: 90 percent.
- 2:49SPEAKER_00: Yeah, 90.
- 2:50SPEAKER_01: That is staggering.
- 2:51SPEAKER_01: That effectively means they aren't a hardware company anymore.
- 2:53SPEAKER_01: They're a utility company.
- 2:54SPEAKER_01: The electric grid for biology.
- 2:56SPEAKER_00: That is the perfect analogy.
- 2:58And this brings us right to the Warren Buffett or Terry Smith
- 3:00framework of investing.
- 3:02SPEAKER_00: Why do those legends love recurring revenue?
- 3:05SPEAKER_01: Predictability.
- 3:05SPEAKER_00: Exactly.
- 3:06SPEAKER_00: Predictability.
- 3:07SPEAKER_00: Illumina sells the sequencer.
- 3:09SPEAKER_00: And frankly,
- 3:09they don't need to make a huge margin on that box because once
- 3:12that box is sitting
- 3:13SPEAKER_00: in a lab,
- 3:14SPEAKER_00: whether it's at Harvard,
- 3:15SPEAKER_00: a hospital in Berlin or a research center in Tokyo,
- 3:18SPEAKER_00: that customer is locked in.
- 3:20SPEAKER_01: Let's clarify that lock-in for a second.
- 3:22SPEAKER_01: Because in some industries,
- 3:23SPEAKER_01: you buy a printer from HP,
- 3:25SPEAKER_01: but you can buy cheap knockoff ink cartridges.
- 3:28SPEAKER_01: You can't do that here, can you?
- 3:29SPEAKER_00: Absolutely not.
- 3:30SPEAKER_00: And that is the moat.
- 3:31SPEAKER_00: This is the high switching cost dynamic.
- 3:33SPEAKER_00: Yeah.
- 3:34To run an aluminum machine,
- 3:35you need their proprietary flow cells,
- 3:37their proprietary reagents.
- 3:39SPEAKER_00: This is chemistry, not just link.
- 3:40SPEAKER_00: It's called sequencing by synthesis, or SBS.
- 3:44SPEAKER_00: Highly protected intellectual property.
- 3:46SPEAKER_00: You cannot just swap in a generic alternative without...
- 3:49SPEAKER_00: compromising the data and in clinical settings.
- 3:52SPEAKER_00: I mean, lives depend on that accuracy.
- 3:53SPEAKER_00: It's a non-starter.
- 3:55So once a lab spends a million dollars on a Novasek machine,
- 3:57they're basically.
- 3:58SPEAKER_00: They're married to Illumina for the life of that machine.
- 4:00SPEAKER_00: Correct.
- 4:01SPEAKER_00: And the installed base,
- 4:03SPEAKER_00: the number of machines active in the field,
- 4:05SPEAKER_00: is the measure of that marriage.
- 4:07The JPM data shows they now have an active installed base
- 4:11around 21,000 units globally.
- 4:13SPEAKER_00: That's 21,000 customers who are,
- 4:16SPEAKER_00: for all practical purposes,
- 4:18mandated to send Illumina checks every single month to keep
- 4:21their labs running.
- 4:22SPEAKER_01: That sounds like an incredible business.
- 4:24SPEAKER_01: High margins, recurring revenue, a defensive moat.
- 4:27SPEAKER_01: So why did the stock chart look like a disaster scene for three years?
- 4:31SPEAKER_01: We have to address the elephant in the room.
- 4:33SPEAKER_00: The $8 billion elephant.
- 4:34SPEAKER_01: Exactly.
- 4:35SPEAKER_01: The grail acquisition.
- 4:36This seems to be the chapter in the history books titled
- 4:39Capital Allocation Failure.
- 4:41SPEAKER_00: Oh, it's a painful read.
- 4:42If you're a shareholder who lived through 2021 to 2024,
- 4:45you have battle scars.
- 4:47SPEAKER_01: Let's unpack it for the listeners who might be new to this saga.
- 4:50SPEAKER_01: What actually happened?
- 4:51SPEAKER_00: So in 2021, Illumina decided to acquire a company called Grail.
- 4:56Now,
- 4:56Grail was actually spun out of Illumina originally,
- 4:59but they wanted to buy it back.
- 5:00SPEAKER_00: Grail makes a blood test for early cancer detection, scientifically.
- 5:04SPEAKER_00: It's the Holy Grail, pun intended.
- 5:06SPEAKER_00: A simple blood draw to find 15 types of cancer.
- 5:09SPEAKER_01: On paper, that sounds noble.
- 5:10SPEAKER_01: It sounds like the future of medicine.
- 5:12But financially...
- 5:13Financially,
- 5:14it was what Peter Lynch might call de-worsification.
- 5:17SPEAKER_00: They agreed to pay roughly $8 billion in cash and stock.
- 5:21SPEAKER_00: But the problem wasn't just the price tag.
- 5:24SPEAKER_00: It was the arrogance.
- 5:25They closed the deal in August 2021,
- 5:27despite antitrust regulators in both Europe and the U.S.
- 5:30SPEAKER_00: screaming, stop!
- 5:31SPEAKER_01: That's rare.
- 5:32SPEAKER_01: Usually when the European Commission says, we're investigating, you wait.
- 5:36SPEAKER_01: You don't just close the deal and say, sue me.
- 5:38SPEAKER_00: Exactly.
- 5:39SPEAKER_00: It was a declaration of war against regulators.
- 5:41SPEAKER_00: And the regulators fought back.
- 5:43SPEAKER_00: The European Commission fined them a record amount.
- 5:44They were forced to hold Grail as a separate entity,
- 5:47so they couldn't integrate the business.
- 5:49SPEAKER_00: They were just burning cash on legal fees every single day.
- 5:52SPEAKER_01: And the financial fallout is right here in the impairment charges.
- 5:55SPEAKER_01: I'm looking at the 2022 report, a $3.9 billion goodwill impairment.
- 6:01For those who aren't accountants,
- 6:02that's just management admitting,
- 6:04whoops,
- 6:04we overpaid.
- 6:05SPEAKER_00: And it didn't stop there.
- 6:07SPEAKER_00: In 2024, they took another hit, about $1.47 billion in impairments.
- 6:11SPEAKER_00: But the real destruction was operational.
- 6:14SPEAKER_00: While they owned Grail, it was bleeding money.
- 6:17We are talking billions in operating losses that drag down the
- 6:20entire company's profitability.
- 6:22SPEAKER_00: That beautiful recurring revenue machine we just talked about,
- 6:25SPEAKER_00: it was being suffocated by the losses from this moonshot project.
- 6:28SPEAKER_01: It was a mess.
- 6:29SPEAKER_01: A textbook example of management losing focus.
- 6:32SPEAKER_01: But looking at where we are today,
- 6:33SPEAKER_01: January 17,
- 6:34SPEAKER_01: 2026,
- 6:34SPEAKER_01: that bandage has finally been ripped off,
- 6:37SPEAKER_01: right?
- 6:37SPEAKER_00: Yes.
- 6:38And that is the pivot point for the investment case we're
- 6:40looking at today.
- 6:41SPEAKER_00: In June 2024, Illumina completed the spinoff of Grail.
- 6:44SPEAKER_00: They gave the business to shareholders,
- 6:46SPEAKER_00: kept a minority stake,
- 6:47SPEAKER_00: but crucially,
- 6:48SPEAKER_00: they got it off their books.
- 6:49SPEAKER_00: It was a clean break.
- 6:50SPEAKER_01: So the bleeding stopped.
- 6:51SPEAKER_00: Effectively, yes.
- 6:52SPEAKER_00: And this lets us do some financial forensics on the new Illumina,
- 6:56SPEAKER_00: or what the reports call core Illumina.
- 6:58SPEAKER_00: If you strip away the Grail disaster,
- 7:00SPEAKER_00: was the underlying business ever actually broken,
- 7:02SPEAKER_00: or was it just obscured by the smoke?
- 7:04Well,
- 7:05looking at the margin recovery in the 2025 reports,
- 7:08it doesn't look broken at all.
- 7:09SPEAKER_00: It really doesn't.
- 7:10SPEAKER_00: And this is where it gets exciting for a value investor.
- 7:13SPEAKER_00: In 2023, amidst all the chaos, the gross margin bottomed out at 60.9%.
- 7:19SPEAKER_00: For a high-tech biocompany, that's concerning.
- 7:21SPEAKER_00: But look at the recovery.
- 7:22SPEAKER_00: In 2024, it climbed back to 65.4%.
- 7:24SPEAKER_00: In the first three quarters of 2025, we're seeing margins hitting 66.3%.
- 7:31SPEAKER_01: That's a significant jump in a short time, over 500 basis points.
- 7:35SPEAKER_01: What's driving that?
- 7:36SPEAKER_01: Is it just getting rid of grail?
- 7:37SPEAKER_00: That's part of it.
- 7:38SPEAKER_00: But you have to give credit to the new management team.
- 7:41SPEAKER_00: The reports highlight operational excellence initiatives.
- 7:44SPEAKER_00: That's corporate speak.
- 7:45SPEAKER_00: But the details matter.
- 7:46SPEAKER_00: They cut freight costs.
- 7:48SPEAKER_00: They optimized their manufacturing footprint.
- 7:50SPEAKER_00: They reduced headcount.
- 7:51And crucially,
- 7:52the product mix shifted back toward those high margin
- 7:55consumables.
- 7:56SPEAKER_01: And we see this even more clearly in the operating income lines.
- 7:59SPEAKER_00: Absolutely.
- 8:00SPEAKER_00: In 2022, the consolidated company posted a $4.2 billion operating loss.
- 8:03SPEAKER_00: It was a bloodbath.
- 8:03SPEAKER_00: In 2024, still a $1.4 billion loss.
- 8:04SPEAKER_00: But look at the year-to-date numbers for Q3 2025.
- 8:07SPEAKER_00: They swung to a positive operating income of $606 million.
- 8:08SPEAKER_00: From a billion-dollar loss to a $600 million profit, the ship has turned.
- 8:23SPEAKER_00: And if you look specifically at Core Illumina,
- 8:24SPEAKER_00: excluding the one-off charges,
- 8:26SPEAKER_00: the operating profit is even stronger,
- 8:28SPEAKER_00: over $1.3 billion year to date in 2025.
- 8:32SPEAKER_00: This proves the thesis.
- 8:33SPEAKER_00: The monopoly was never broken.
- 8:35SPEAKER_00: The management of the monopoly was broken.
- 8:36SPEAKER_00: Now that that is fixed, the earnings power is revealing itself.
- 8:39SPEAKER_01: Okay, so costs are under control.
- 8:41SPEAKER_01: Margins are up.
- 8:42SPEAKER_01: But you can cut costs all day.
- 8:44SPEAKER_01: Eventually, you need to grow.
- 8:45SPEAKER_01: And this brings us to the new flagship product, the Novasec X.
- 8:49SPEAKER_00: This is the key metric deep dive.
- 8:51SPEAKER_00: The Novasec X launched in 2023.
- 8:53SPEAKER_00: It's their super high throughput machine.
- 8:55SPEAKER_00: It can sequence genomes faster and cheaper than anything before it.
- 8:58Now,
- 8:58usually when a company launches new hardware,
- 9:00margins take a hit initially.
- 9:01SPEAKER_01: Right.
- 9:01SPEAKER_01: The short term pain for long term gain.
- 9:03SPEAKER_01: You have to build new production lines, discount the old inventory.
- 9:06SPEAKER_00: Exactly.
- 9:07SPEAKER_00: And we saw that pain in 2023 in early 2024.
- 9:08SPEAKER_00: But here's the payoff.
- 9:12The JPM 2026 update shows they placed over 95 of these units in
- 9:17Q4 2025 alone.
- 9:20SPEAKER_00: They now have an active installed base of about 890 Novasec X units.
- 9:25SPEAKER_01: I want to pause on the revenue numbers here,
- 9:26SPEAKER_01: though,
- 9:26SPEAKER_01: because this is where I get a little skeptical.
- 9:28SPEAKER_01: I'm looking at the breakdown for 2025.
- 9:31Instrument revenue selling the actual machines is actually down
- 9:34year over year,
- 9:35SPEAKER_01: down roughly 5 to 9 percent.
- 9:37SPEAKER_01: How is this a success if sales of the flagship product are dropping?
- 9:41SPEAKER_00: That is the revenue paradox.
- 9:42And if you don't understand the razor blade model,
- 9:44you will look at that number and panic.
- 9:46SPEAKER_00: In fact, that's why the stock has been so volatile.
- 9:48SPEAKER_00: Investors see instrument revenue down and think demand is drying up.
- 9:51SPEAKER_00: But smart capital sees consumable revenue up.
- 9:53SPEAKER_01: Because the market is saturated with the hardware.
- 9:55SPEAKER_00: Partially.
- 9:56SPEAKER_00: But it means the placement cycle is maturing.
- 9:59SPEAKER_00: Think of it this way.
- 10:00SPEAKER_00: They've sold the razors.
- 10:01SPEAKER_00: The heavy lifting is done.
- 10:03Now,
- 10:03those 890 Novasec X units,
- 10:06plus the thousands older machines,
- 10:08are running 247.
- 10:09SPEAKER_00: They're churning through consumables.
- 10:12The fact that instrument revenue is down while consumable
- 10:14revenue is up is a signal
- 10:16SPEAKER_00: that the flywheel is working.
- 10:18SPEAKER_00: Utilization is growing.
- 10:19SPEAKER_00: They are harvesting the crop they planted.
- 10:21It's a transition from a hardware sales cycle to a recurring
- 10:24revenue harvest?
- 10:25SPEAKER_00: Convisely.
- 10:25SPEAKER_00: It's an infrastructure play.
- 10:27And there's another subtle signal in the 2025 data that shows
- 10:29management is confident.
- 10:31SPEAKER_00: Share count stability.
- 10:32SPEAKER_01: Right, because they diluted shareholders to buy Grail.
- 10:35SPEAKER_00: They issued a massive amount of stock.
- 10:37But since the spinoff,
- 10:38the share count has stabilized around 157 to 159 million
- 10:40shares.
- 10:43SPEAKER_00: Management isn't treating stock like monopoly money anymore.
- 10:46SPEAKER_00: They're protecting the equity.
- 10:47SPEAKER_00: That's a massive shift in corporate culture.
- 10:49SPEAKER_01: Which brings us back to your earlier provocative comparison.
- 10:52SPEAKER_01: You said Illumina in 2026 reminds you of Apple in 2012.
- 10:57Connect those dots for us because Apple is a consumer brand and
- 11:00Illumina is deep tech.
- 11:02SPEAKER_01: Where's the parallel?
- 11:03SPEAKER_00: It's all about investor psychology and pattern recognition.
- 11:06SPEAKER_00: Think back to 2012.
- 11:08SPEAKER_00: Apple stock was trading at a P.E.
- 11:09SPEAKER_00: of like 10 or 12.
- 11:11SPEAKER_00: Dirt cheap.
- 11:13SPEAKER_00: Why?
- 11:13Because Wall Street was terrified that iPhone sales,
- 11:16the hardware slowing down.
- 11:18SPEAKER_00: The narrative was peak iPhone.
- 11:20SPEAKER_01: I remember that.
- 11:21SPEAKER_01: The peak Apple narrative was everywhere.
- 11:23SPEAKER_00: Right.
- 11:23SPEAKER_00: But what did the market miss?
- 11:24SPEAKER_00: They missed the transition to the ecosystem.
- 11:27SPEAKER_00: They missed the App Store,
- 11:28SPEAKER_00: iCloud,
- 11:29SPEAKER_00: Apple Music,
- 11:31SPEAKER_00: the high margin recurring revenue that comes after you buy the phone.
- 11:34SPEAKER_01: And you see the exact same pattern here.
- 11:35SPEAKER_00: It is identical.
- 11:37Investors today are looking at Illumina and worrying about
- 11:40slowing increment sales.
- 11:41SPEAKER_00: They're saying the sequencer market is saturated, growth is dead.
- 11:44SPEAKER_00: They are missing the transition to 90% recurring revenue.
- 11:48Just like Apple transitioned from being valued as a hardware
- 11:50company to an
- 11:51SPEAKER_00: ecosystem company,
- 11:53SPEAKER_00: Illumina has made that same leap.
- 11:55SPEAKER_00: It's an infrastructure monopoly.
- 11:56SPEAKER_01: And there's a governance parallel too, right?
- 11:58SPEAKER_00: Yes.
- 11:59SPEAKER_00: Big tech giants often have to fix their governance to unlock value.
- 12:04SPEAKER_00: Apple started massive buybacks.
- 12:06Illumina fixed its governance by admitting the mistake and
- 12:09spinning off grail.
- 12:10SPEAKER_00: That removes the governance discount applied to the stock.
- 12:13SPEAKER_01: So the valuation has been compressed by the noise and the fear,
- 12:16SPEAKER_01: but the intrinsic value of the monopoly is still there.
- 12:19SPEAKER_01: Let's look at the future then.
- 12:21SPEAKER_01: What does the guidance look like?
- 12:22SPEAKER_00: The JPM preliminary results are very encouraging.
- 12:25SPEAKER_00: For Q4 2025, they posted revenue of about $1.155 billion.
- 12:26SPEAKER_00: That represents roughly 4% year-over-year growth.
- 12:33SPEAKER_01: Okay, to play devil's advocate again, 4% is not exactly hypergrowth.
- 12:37SPEAKER_01: That's barely beating inflation.
- 12:38SPEAKER_00: You're right.
- 12:39SPEAKER_00: It's not a rocket ship.
- 12:40SPEAKER_00: But you have to look at the context.
- 12:42After years of shrinking or flat revenues,
- 12:44positive growth signals that the patient has a pulse.
- 12:47SPEAKER_00: It's an inflection point.
- 12:48SPEAKER_00: And look at the earnings.
- 12:49The non-GAAP EPS forecast for fiscal year 25 is coming in
- 12:53between $4.76 and $4.79.
- 12:56SPEAKER_01: That puts them on very solid footing.
- 12:58SPEAKER_01: And are there any new catalysts?
- 13:00SPEAKER_01: Or is it just the Novisex show?
- 13:02SPEAKER_00: No, they are innovating.
- 13:03They mentioned the launch of the MISIC i100 and something
- 13:05called five-base genomic sequencing.
- 13:08SPEAKER_01: Can you translate five-base for us?
- 13:10SPEAKER_01: I thought DNA only had four bases, A, C, T, and G. It does.
- 13:15SPEAKER_00: But five-base sequencing lets researchers see epigenetic modifications,
- 13:19SPEAKER_00: changes to the DNA structure,
- 13:21SPEAKER_00: without a separate test.
- 13:23SPEAKER_00: It basically makes the machine smarter and more valuable.
- 13:26SPEAKER_00: These new products target the mid-throughput market, smaller labs.
- 13:29SPEAKER_00: It reinforces that ecosystem lock-in.
- 13:32So if I'm an investor looking at this today,
- 13:34what is the bull case for returns?
- 13:36SPEAKER_01: If growth is only 4%, where does the profit come from?
- 13:39SPEAKER_00: The bull case isn't that revenue is going to suddenly double.
- 13:41SPEAKER_00: The bull case is valuation reversion.
- 13:44SPEAKER_00: You have a company that dominates its field,
- 13:46SPEAKER_00: a monopoly on genomic data,
- 13:48SPEAKER_00: trading at a depressed multiple because of three years of bad headlines.
- 13:51SPEAKER_01: The grail discount.
- 13:52SPEAKER_00: Exactly.
- 13:52SPEAKER_00: Exactly.
- 13:53SPEAKER_00: If that discount evaporates and the P.E.
- 13:56SPEAKER_00: multiple reverts to the industry mean,
- 13:59SPEAKER_00: which it should,
- 14:00SPEAKER_00: given the 90 percent recurring revenue,
- 14:02SPEAKER_00: you could see a can G.R.
- 14:04SPEAKER_00: of 30 percent or more over the next 18 months,
- 14:06SPEAKER_00: just from the stock price catching up to the business reality.
- 14:09The margin of safety here is that the current price reflects
- 14:12maximum pessimism,
- 14:14SPEAKER_00: while the financials reflect a recovered business.
- 14:16SPEAKER_01: That's a compelling setup.
- 14:18SPEAKER_01: It's like buying a house that had a hole in the roof,
- 14:20SPEAKER_01: but the owner just fixed it repainted,
- 14:22and the market hasn't noticed yet because they're still looking
- 14:25at photos from
- 14:25SPEAKER_01: 2023.
- 14:26SPEAKER_00: That's a great analogy.
- 14:27SPEAKER_00: The house is solid.
- 14:28SPEAKER_00: The hole is gone.
- 14:29Before we wrap up,
- 14:30I want to leave our listeners with one final,
- 14:32slightly provocative thought.
- 14:33We talked about the Grail spinoff as a clean break,
- 14:36but it wasn't a total break,
- 14:38was it?
- 14:38SPEAKER_00: No, it wasn't.
- 14:39SPEAKER_00: As part of the deal, Illumina retained a 14.5% minority stake in Grail.
- 14:45SPEAKER_01: So here's the question.
- 14:46SPEAKER_01: Right now,
- 14:47SPEAKER_01: based on the stock price,
- 14:48SPEAKER_01: the market is effectively valuing that stake at zero,
- 14:51SPEAKER_01: or close to it.
- 14:52SPEAKER_00: That's fair.
- 14:53SPEAKER_00: GRAIL is still unprofitable.
- 14:54SPEAKER_01: GRAIL's technology actually works.
- 14:55SPEAKER_01: We know that.
- 14:56SPEAKER_01: The science is sound.
- 14:57SPEAKER_00: It is.
- 14:58SPEAKER_00: The challenge is adoption and insurance reimbursement, not the science.
- 15:02SPEAKER_01: But what if they crack that code?
- 15:03SPEAKER_01: If GRAIL eventually succeeds outside of Illumina?
- 15:06SPEAKER_00: Then Illumina shareholders are holding a free lottery ticket.
- 15:09If GRAIL becomes a $50 billion company in a decade,
- 15:13which isn't impossible,
- 15:15SPEAKER_00: That 14.5% stake is worth billions.
- 15:18And right now,
- 15:19as an Illumina shareholder,
- 15:21you aren't paying a dime for it.
- 15:23SPEAKER_00: It's pure optionality.
- 15:24SPEAKER_00: A free lottery ticket on curing cancer.
- 15:26SPEAKER_00: I'll take those odds.
- 15:27SPEAKER_00: It's certainly the cherry on top of the thesis.
- 15:30SPEAKER_00: But even without the cherry, the cake looks pretty good.
- 15:32SPEAKER_01: Well, there you have it.
- 15:33SPEAKER_00: Yeah.
- 15:33From a capital allocation disaster to a lean,
- 15:36mean recurring revenue machine,
- 15:39It's a classic case of looking past the headlines and reading
- 15:42the footnotes.
- 15:42SPEAKER_00: Always read the footnotes.
- 15:44SPEAKER_01: As always, don't just take our word for it.
- 15:45SPEAKER_01: Go read the 10Ks.
- 15:47SPEAKER_01: Look at the cash flow statements.
- 15:48SPEAKER_01: The story is always in the numbers.
- 15:50SPEAKER_01: Thanks for listening to The Deep Dive.
- 15:51SPEAKER_01: We'll catch you next time.